The CheckMate 816 trial [11] was the first phase III trial of neoadjuvant chemo-immunotherapy in resectable NSCLC to be presented, comparing three cycles of neoadjuvant nivolumab 360 mg every 21 days plus platinum doublet chemotherapy with chemotherapy alone in 358 patients with EGFR and ALK-negative stage IB (≥4 cm) to IIIA NSCLC (AJCC Staging Manual, 7th edition). Here, EGFR is linked to non-small cell lung carcinoma.